Rituximab for Treatment of Checkpoint Inhibitor Induced Immune Related Adverse Events

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525728-18-00

Enrollment

Registered

2026-03-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All CTCAE (v. 6.0) grade 2-4 immune-related adverse events

None listed

Sex/Gender

All

Age

18 Years to No maximum

None listed

Source: EU CTIS · Data processed: Mar 31, 2026